IL152868A0 - NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11beta-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17alpha -METHOXYMETHYL-17beta-METHOXY-ESTRA-4,9-DIEN-3-ONE - Google Patents

NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11beta-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17alpha -METHOXYMETHYL-17beta-METHOXY-ESTRA-4,9-DIEN-3-ONE

Info

Publication number
IL152868A0
IL152868A0 IL15286801A IL15286801A IL152868A0 IL 152868 A0 IL152868 A0 IL 152868A0 IL 15286801 A IL15286801 A IL 15286801A IL 15286801 A IL15286801 A IL 15286801A IL 152868 A0 IL152868 A0 IL 152868A0
Authority
IL
Israel
Prior art keywords
11beta
17alpha
hydroxyiminomethyl
17beta
methoxymethyl
Prior art date
Application number
IL15286801A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL152868A0 publication Critical patent/IL152868A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15286801A 2000-05-23 2001-05-09 NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11beta-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17alpha -METHOXYMETHYL-17beta-METHOXY-ESTRA-4,9-DIEN-3-ONE IL152868A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00110887A EP1157996A1 (de) 2000-05-23 2000-05-23 Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
PCT/EP2001/005237 WO2001090137A2 (de) 2000-05-23 2001-05-09 NEUE FESTKÖRPERFORMEN DES MESOPROGESTINS 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ON

Publications (1)

Publication Number Publication Date
IL152868A0 true IL152868A0 (en) 2003-06-24

Family

ID=8168805

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15286801A IL152868A0 (en) 2000-05-23 2001-05-09 NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11beta-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17alpha -METHOXYMETHYL-17beta-METHOXY-ESTRA-4,9-DIEN-3-ONE
IL152868A IL152868A (en) 2000-05-23 2002-11-14 Forms of solid bodies of mezoprogestin ß 11 - [E - 4 (hydroxyiminomethyl) - phenyl] - a17 - methoxymethyl - ß17 - methoxy - astra - 9, 4 dian - 3 - on

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL152868A IL152868A (en) 2000-05-23 2002-11-14 Forms of solid bodies of mezoprogestin ß 11 - [E - 4 (hydroxyiminomethyl) - phenyl] - a17 - methoxymethyl - ß17 - methoxy - astra - 9, 4 dian - 3 - on

Country Status (30)

Country Link
US (1) US7799770B2 (ru)
EP (3) EP1157996A1 (ru)
JP (1) JP2003534350A (ru)
KR (1) KR100553292B1 (ru)
CN (1) CN100384867C (ru)
AT (1) ATE397617T1 (ru)
AU (2) AU2001256344B2 (ru)
BG (1) BG65968B1 (ru)
BR (1) BR0111058A (ru)
CA (1) CA2409869C (ru)
CZ (1) CZ2003620A3 (ru)
DE (1) DE50114012D1 (ru)
DK (1) DK1292607T3 (ru)
EA (1) EA005623B1 (ru)
EC (2) ECSP024358A (ru)
ES (1) ES2307613T3 (ru)
HR (2) HRP20021032B1 (ru)
HU (1) HUP0301956A3 (ru)
IL (2) IL152868A0 (ru)
ME (1) MEP15608A (ru)
MX (1) MXPA02011524A (ru)
NO (1) NO327004B1 (ru)
NZ (1) NZ522768A (ru)
PL (1) PL358789A1 (ru)
PT (1) PT1292607E (ru)
RS (1) RS50493B (ru)
SK (1) SK2922003A3 (ru)
UA (1) UA73988C2 (ru)
WO (1) WO2001090137A2 (ru)
ZA (1) ZA200209322B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
WO2006078731A2 (en) * 2005-01-18 2006-07-27 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same
US20090054387A1 (en) 2006-04-18 2009-02-26 Detlef Grawe Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil)
DE102006018888A1 (de) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19610667C2 (de) * 1996-03-08 1998-04-09 Schering Ag (Z)-11ß-[4-(Dimethylamino)phenyl]17ß-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-on als kristallines Ansolvat
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
ZA200209322B (en) 2005-03-10
ECSP084358A (es) 2008-11-27
EP1862469A2 (de) 2007-12-05
NO20025613D0 (no) 2002-11-22
CA2409869C (en) 2009-02-03
HUP0301956A2 (hu) 2003-09-29
DK1292607T3 (da) 2008-10-13
NZ522768A (en) 2005-03-24
PL358789A1 (en) 2004-08-23
BG65968B1 (bg) 2010-07-30
JP2003534350A (ja) 2003-11-18
EA200201192A1 (ru) 2003-06-26
AU2001256344B8 (en) 2001-12-03
CA2409869A1 (en) 2002-11-20
HUP0301956A3 (en) 2010-03-29
AU5634401A (en) 2001-12-03
ECSP024358A (es) 2003-03-31
MEP15608A (en) 2010-06-10
SK2922003A3 (en) 2003-08-05
MXPA02011524A (es) 2004-09-10
US20040006241A1 (en) 2004-01-08
KR100553292B1 (ko) 2006-02-22
ATE397617T1 (de) 2008-06-15
UA73988C2 (en) 2005-10-17
YU88702A (sh) 2006-01-16
IL152868A (en) 2009-08-03
ES2307613T3 (es) 2008-12-01
CN100384867C (zh) 2008-04-30
DE50114012D1 (en) 2008-07-17
HRP20021032B1 (en) 2008-09-30
WO2001090137A2 (de) 2001-11-29
CN1430624A (zh) 2003-07-16
CZ2003620A3 (cs) 2003-08-13
EP1157996A1 (de) 2001-11-28
WO2001090137A3 (de) 2002-04-04
PT1292607E (pt) 2008-09-15
EP1292607B1 (de) 2008-06-04
NO20025613L (no) 2002-11-22
AU2001256344B2 (en) 2007-01-25
BG107557A (bg) 2004-01-30
RS50493B (sr) 2010-03-02
EP1292607A2 (de) 2003-03-19
BR0111058A (pt) 2003-04-15
EA005623B1 (ru) 2005-04-28
HRP20080423A2 (en) 2008-10-31
US7799770B2 (en) 2010-09-21
HRP20021032A2 (en) 2005-02-28
NO327004B1 (no) 2009-04-06
KR20030028742A (ko) 2003-04-10

Similar Documents

Publication Publication Date Title
IL152868A0 (en) NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11beta-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17alpha -METHOXYMETHYL-17beta-METHOXY-ESTRA-4,9-DIEN-3-ONE
US4943566A (en) Novel 17-aryl-steroids
DK2623510T3 (en) 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9 (10) -DIEN-11-ARYL DERIVATIVES, METHOD OF PREPARING IT AND THEIR USE FOR THE TREATMENT OF DISEASES
CA2768448A1 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylene oxyalkylene aryl derivatives, methods for the production thereof and the use thereof for treating diseases
SK283155B6 (sk) 17alfa-Fluóralkylsteroidy, farmaceutické prostriedky tieto látky obsahujúce a ich použitie
JP2911553B2 (ja) １１β―アリール―４―エストレン、その製法、中間生成物及び新規化合物を含有する抗ゲスタゲン及び抗グルココルチコイド作用を有する製薬学的製済
EP0865167A3 (en) Power saving scheme for a digital wireless communications terminal
MXPA02006365A (es) Surtidor de panos limpiadores humedos y sistema de montaje.
WO2004041839A3 (en) Synthesis of estetrol via estrone derived steroids
HU208021B (en) Process for producing 13-alyl-11-beta-phenyl-gonane derivatives and pharmaceutical compositions containing them
AU2001256344A1 (en) Novel solid body forms of mesoprogestin 11beta-[4e-(hydroxyiminomethyl)-phenyl]-17alpha-methoxymethy -17beta-methoxy-estra-4,9-dien-3-one
WO2000045772A3 (en) Apparatus and method for treating objectionable odors in toilet bowls and the like
JP2999258B2 (ja) １０β―Ｈ―ステロイドの製法
TW200510406A (en) Polymorphs of cabergoline
DE60209248D1 (de) Verwendung von (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)-estra-4,9-dien-3-on zur behandlung von schweren depressionen
HU221728B1 (hu) 10béta-H-szteroid intermedierek és eljárás azok előállítására
Connolly et al. Synthesis and progesterone receptor binding affinity of substituted 1-phenyl-7-benzyl-4, 5, 6, 7-tetrahydro-1H-indazoles
JP2003517001A (ja) 芳香族側鎖中にフルオロアルキル基を有する１１β−フェニルエストラジエン誘導体、その製造法および該化合物を含有する医薬組成物
RU2006124546A (ru) Способ и система для основанной на пакетах работы без последовательного соединения
WO2002101014A3 (en) A process for making estra-4,9(10)-diene steroids
周向东 et al. A new synthesis of A-nor-△^(3 (5), 9 (10)) estradiene-2, 17-dione
MXPA00003695A (en) Estra-1,3,5(10)-triene-7alpha-thioethers
UA36367A (ru) Кальция сукцинат, который имеет кардиотоническое действие
MXPA99007057A (es) Esteroides con actividad antigestagena que tienen una cadena fluorada de 17-alfa-alquilo